Legal & Disputes
Schall, Brown & Schwartz Investigates Artiva Biotherapeutics Over AlloNK Discontinuation
By News Desk ·
Key takeaways
- Schall, Brown & Schwartz LLP is investigating Artiva Biotherapeutics for possible securities law violations tied to statements made to investors.
- Artiva discontinued development of AlloNK (AB-101) on October 27, 2026, citing long-term clinical data and safety incidents.
- Artiva shares fell nearly 30.7% on the day the AlloNK discontinuation was announced.
Schall, Brown & Schwartz LLP is investigating Artiva Biotherapeutics, Inc. for violations of the securities laws, the firm said in a Business Wire announcement on November 17, 2026. The investigation concerns whether Artiva issued false or misleading statements or failed to disclose information pertinent to investors.
What the SBS Investigation Covers
The investigation centers on Artiva's October 27, 2026 announcement that it was discontinuing development efforts related to AlloNK (AB-101). According to the firm, Artiva said the decision rested on long-term clinical data and safety incidents. Artiva shares fell nearly 30.7% the same day.
Schall, Brown & Schwartz describes itself as a national shareholder rights litigation firm that represents investors in securities class actions and shareholder rights matters. Its founding partners are Brian Schall, Andrew Brown and David Schwartz. The firm invited shareholders who suffered a loss to participate and to contact Brian Schall or David Schwartz to discuss their rights free of charge.
The same firm has opened a similar investigation elsewhere. PRESSBEE reported on November 16, 2026 that SBS Law announced an investigation of claims on behalf of Amdocs Limited investors for securities violations.
Artiva's Financing Before the AlloNK Halt
According to akta.pro company records, Artiva raised approximately $300 million in May 2026 through an underwritten offering of common stock and pre-funded warrants at $11.52 per share. The company said at the time that the proceeds would fund Phase 3 trial costs, establishment of a global clinical hub and commercialization preparation for AlloNK in refractory rheumatoid arthritis. The same records show the round drew 13 investors, among them RA Capital, Blackstone, Venrock, Viking Global, GC Holdings and GC Cell. Artiva's total funding stands at $498 million, with the last round dated May 8, 2026.
Earlier Artiva Developments
On October 27, 2026, Artiva announced a strategic update and said it would discontinue development of AlloNK, its allogeneic NK cell therapy for autoimmune diseases, after updated clinical data and two Grade 5 safety events, GlobeNewswire reported. MarketBeat reported the same day that Wedbush reiterated a neutral rating on Artiva with a $4.00 price target.
On November 12, 2026, Pomerantz LLP said it was investigating securities fraud claims on behalf of Artiva investors, following the halt of the lead NK cell therapy program, a 94% workforce cut and a 30.68% stock drop to $4.27 per share, PR Newswire reported. FinancialContent reported on November 13, 2026 that Levi & Korsinsky notified investors of an investigation into Artiva, after the AlloNK discontinuation sent the stock down 30.68% to $4.27 on October 27, 2026.
Artiva's Remaining Pipeline
Artiva is a San Diego-based, pre-revenue cell therapy company founded in 2019, according to akta.pro company records. In June 2026 it received FDA Regenerative Medicine Advanced Therapy designation for AlloNK plus rituximab in refractory rheumatoid arthritis, ahead of a planned Phase 3 registrational trial, the same records show.